{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:48:36Z","timestamp":1770065316198,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ackdjournal.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1053\/j.ackd.2018.10.004","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T17:17:11Z","timestamp":1552411031000},"page":"41-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pathophysiology and Treatment of Hepatitis B and C Infections in Patients With End-Stage Renal Disease"],"prefix":"10.1053","volume":"26","author":[{"given":"Vivek","family":"Soi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantale","family":"Daifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.ackd.2018.10.004_bib1","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease","volume":"3","author":"Kato","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.10.004_bib2","series-title":"Hepatitis B: Are You At Risk?","year":"2010"},{"issue":"5","key":"10.1053\/j.ackd.2018.10.004_bib3","doi-asserted-by":"crossref","first-page":"a021410","DOI":"10.1101\/cshperspect.a021410","article-title":"Hepatitis B virus epidemiology","volume":"5","author":"MacLachlan","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1053\/j.ackd.2018.10.004_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cld.2010.05.007","article-title":"Natural history of chronic hepatitis B","volume":"14","author":"McMahon","year":"2010","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1053\/j.ackd.2018.10.004_bib5","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1046\/j.1523-1755.2003.00017.x","article-title":"Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS","volume":"63","author":"Burdick","year":"2003","journal-title":"Kidney Int"},{"issue":"18","key":"10.1053\/j.ackd.2018.10.004_bib6","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1053\/j.ackd.2018.10.004_bib7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/hep.27978","article-title":"Toward a more accurate estimate of the prevalence of hepatitis C in the United States","volume":"62","author":"Edlin","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10","key":"10.1053\/j.ackd.2018.10.004_bib8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003-2013","volume":"62","author":"Ly","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"21","key":"10.1053\/j.ackd.2018.10.004_bib9","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","article-title":"Membranous nephropathy related to hepatitis B virus in adults","volume":"324","author":"Lai","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2018.10.004_bib10","first-page":"Od25","article-title":"Vasculitis as a presenting manifestation of chronic hepatitis B virus infection: a case report","volume":"10","author":"Singh","year":"2016","journal-title":"J Clin Diagn Res"},{"issue":"10","key":"10.1053\/j.ackd.2018.10.004_bib11","doi-asserted-by":"crossref","first-page":"e3057","DOI":"10.1097\/MD.0000000000003057","article-title":"High mortality of cirrhotic patients with end-stage renal disease","volume":"95","author":"Hung","year":"2016","journal-title":"Medicine"},{"issue":"4","key":"10.1053\/j.ackd.2018.10.004_bib12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3904\/kjim.2014.328","article-title":"Liver cirrhosis leads to poorer survival in patients with end-stage renal disease","volume":"31","author":"Kim","year":"2016","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1053\/j.ackd.2018.10.004_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.icb.7100009","article-title":"Immunopathogenesis of hepatitis B virus infection","volume":"85","author":"Chang","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"10.1053\/j.ackd.2018.10.004_bib14","series-title":"Epidemiology and Prevention of Vaccine-Preventable Diseases: Hepatitis B","year":"2017"},{"key":"10.1053\/j.ackd.2018.10.004_bib15","series-title":"MacSween's Pathology of the Liver","year":"2007"},{"key":"10.1053\/j.ackd.2018.10.004_bib16","series-title":"Viral Hepatitis Serology Training: Hepatitis B","year":"2015"},{"issue":"suppl_8","key":"10.1053\/j.ackd.2018.10.004_bib17","doi-asserted-by":"crossref","first-page":"S765","DOI":"10.1093\/infdis\/jix356","article-title":"Immunopathogenesis of hepatitis B virus","volume":"216","author":"Tseng","year":"2017","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1053\/j.ackd.2018.10.004_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1053\/j.ackd.2018.10.004_bib19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.14218\/JCTH.2015.00018","article-title":"Hepatitis B and delta virus: advances on studies about interactions between the two viruses and the infected hepatocyte","volume":"3","author":"Giersch","year":"2015","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1053\/j.ackd.2018.10.004_bib20","first-page":"104","article-title":"Antigen detection of hepatitis D virus infection among renal failure patients with hepatitis B viruses on hemodialysis in Khartoum State","volume":"2","author":"Ahmed","year":"2018","journal-title":"J Microbiol Pathol"},{"key":"10.1053\/j.ackd.2018.10.004_bib21","series-title":"Viral Hepatitis: Hepatitis D","year":"2018"},{"key":"10.1053\/j.ackd.2018.10.004_bib22","series-title":"What is hepatitis D?","year":"2018"},{"key":"10.1053\/j.ackd.2018.10.004_bib23","series-title":"Hepatitis D","year":"2017"},{"issue":"3","key":"10.1053\/j.ackd.2018.10.004_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1515\/jtim-2015-0018","article-title":"Viral hepatitis in hemodialysis: an update","volume":"3","author":"Bernieh","year":"2015","journal-title":"J Transl Intern Med"},{"issue":"5","key":"10.1053\/j.ackd.2018.10.004_bib25","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/ki.2013.249","article-title":"Treatment of hepatitis B in patients with chronic kidney disease","volume":"84","author":"Pipili","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2018.10.004_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/apt.12538","article-title":"Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease","volume":"39","author":"Pipili","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1053\/j.ackd.2018.10.004_bib27","first-page":"784","article-title":"The prevalence of occult hepatitis B virus in the hemodialysis patients in Yazd, Iran","volume":"54","author":"Ayatollahi","year":"2016","journal-title":"Acta Med Iran"},{"issue":"4","key":"10.1053\/j.ackd.2018.10.004_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1665-2681(19)31335-3","article-title":"Occult hepatitis B in patients on hemodialysis: a review","volume":"12","author":"Fontenele","year":"2013","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1053\/j.ackd.2018.10.004_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1744-9987.2009.00798.x","article-title":"Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: a multicenter study","volume":"14","author":"Aghakhani","year":"2010","journal-title":"Ther Apher Dial"},{"issue":"10","key":"10.1053\/j.ackd.2018.10.004_bib30","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/jmv.24008","article-title":"Prevalence of occult HBV among hemodialysis patients in two districts in the northern part of the West Bank, Palestine","volume":"86","author":"Dumaidi","year":"2014","journal-title":"J Med Virol"},{"issue":"9","key":"10.1053\/j.ackd.2018.10.004_bib31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/dat.20258","article-title":"Prevalence of occult hepatitis B infection in hemodialysis patients","volume":"37","author":"Ersoy","year":"2008","journal-title":"Dial Transplant"},{"issue":"6","key":"10.1053\/j.ackd.2018.10.004_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/eri.10.47","article-title":"Preventing infections in patients undergoing hemodialysis","volume":"8","author":"Kallen","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1053\/j.ackd.2018.10.004_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"9","key":"10.1053\/j.ackd.2018.10.004_bib34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5301\/ijao.5000437","article-title":"Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks","volume":"38","author":"Fabrizi","year":"2015","journal-title":"Int J Artif Organs"},{"issue":"Rr-5","key":"10.1053\/j.ackd.2018.10.004_bib35","first-page":"1","article-title":"Recommendations for preventing transmission of infections among chronic hemodialysis patients","volume":"50","year":"2001","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1053\/j.ackd.2018.10.004_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/JCM.43.1.414-420.2005","article-title":"Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients","volume":"43","author":"Fabrizi","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.ackd.2018.10.004_bib37","series-title":"APIC Recommended Revisions to Conditions for Coverage for End-Stage Renal Disease Facilities","year":"2015"},{"issue":"4","key":"10.1053\/j.ackd.2018.10.004_bib38","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1128\/JCM.40.4.1541-1545.2002","article-title":"Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit","volume":"40","author":"Halfon","year":"2002","journal-title":"J Clin Microbiol"},{"issue":"27","key":"10.1053\/j.ackd.2018.10.004_bib39","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.ackd.2018.10.004_bib40","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2018.10.004_bib41","series-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases\/Infectious Diseases Society of America. HCVguidelines.org","year":"2018"},{"issue":"10003","key":"10.1053\/j.ackd.2018.10.004_bib42","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"15","key":"10.1053\/j.ackd.2018.10.004_bib43","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1053\/j.ackd.2018.10.004_bib44","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/S0168-8278(18)30803-1","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1-6 infection [abstract]","volume":"68","author":"Persico","year":"2018","journal-title":"J Hepatol"},{"issue":"7","key":"10.1053\/j.ackd.2018.10.004_bib45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"issue":"S1","key":"10.1053\/j.ackd.2018.10.004_bib46","first-page":"441A","article-title":"RUBY-I: safety and efficacy of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without ribavirin in adults with genotype 1 chronic hepatitis C virus (HCV) infection with severe renal impairment or end-stage renal disease [abstract]","volume":"64","author":"Vierling","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"S1","key":"10.1053\/j.ackd.2018.10.004_bib47","first-page":"470A","article-title":"RUBY-II: efficacy and safety of a ribavirin-free ombitasvir\/paritaprevir\/ritonavir \u00b1 dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotypes 1a or 4 infection [abstract]","volume":"64","author":"Gane","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1 Suppl","key":"10.1053\/j.ackd.2018.10.004_bib48","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0168-8278(17)30444-0","article-title":"MAGELLAN-2: safety and efficacy of glecaprevir\/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection [abstract]","volume":"66","author":"Reau","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1053\/j.ackd.2018.10.004_bib49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"issue":"2","key":"10.1053\/j.ackd.2018.10.004_bib50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ackd.2018.10.004_bib51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12916-017-0815-7","article-title":"Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals","volume":"15","author":"Baumert","year":"2017","journal-title":"BMC Med"},{"issue":"5","key":"10.1053\/j.ackd.2018.10.004_bib52","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/TP.0000000000001410","article-title":"Use of HCV+ donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation","volume":"101","author":"Sawinski","year":"2017","journal-title":"Transplantation"},{"issue":"5","key":"10.1053\/j.ackd.2018.10.004_bib53","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559518302179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559518302179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T04:05:47Z","timestamp":1574309147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559518302179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1548559518302179"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2018.10.004","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology and Treatment of Hepatitis B and C Infections in Patients With End-Stage Renal Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}